ERBB2 and gastroesophageal junction adenocarcinoma: Zolbetuximab continues to be investigated as first-line treatment in two phase 3 trials in combination with either capecitabine/oxaliplatin (Xu et al. 2020) or mFOLFOX6 (Shitara et al. 2020) in claudin 18.2 + /HER2 − advanced or metastatic G/GEJ adenocarcinomas.